CoreComm Internet

Features

Make this your home page

FDA plans ultra-fast review of three psychedelic drugs following Trump directive

WASHINGTON (AP) — The Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest step by the Trump administration toward possible approval of the experimental treatments. President Donald Trump signed an executive order last weekend directing the FDA and other federal agencies to speed research and loosen restrictions on psychedelics, a class of hallucinogenic drugs it...

Read More
 

----------
Copyright 2026 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

CoreComm is not responsible for content on external sites. Please review the privacy and security policies of each vendor before making online purchases or providing personal information. Forecast Information Provided by AccuWeather.